117 related articles for article (PubMed ID: 31072433)
1. Anti-Colorectal Cancer Effect via Application of Polyethylene Glycol Modified Liposomal Apatinib.
Hu Y; Zhou P; Lin Y; Yang D; Wang B
J Biomed Nanotechnol; 2019 Jun; 15(6):1256-1266. PubMed ID: 31072433
[TBL] [Abstract][Full Text] [Related]
2. Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer.
Hu Y; Wu C; Zhu C; Fu Q; Guo J; Deng L; He Y; Yang D; Cheng Y; Gao X
Int J Pharm; 2018 Dec; 552(1-2):319-327. PubMed ID: 30308269
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.
Song Z; Lin Y; Zhang X; Feng C; Lu Y; Gao Y; Dong C
Int J Nanomedicine; 2017; 12():1941-1958. PubMed ID: 28331317
[TBL] [Abstract][Full Text] [Related]
4. Oral Administration of Liposome-Apatinib and Locally Delivery of Docetaxel/MPEG-PCL by Fibrin Glue Synergistically Improve Therapeutic Effect in Colorectal Cancer.
Yu T; Wu C; Zhu C; He Y; Yang D; Cheng Y; Gao X
J Biomed Nanotechnol; 2018 Dec; 14(12):2077-2091. PubMed ID: 30305215
[TBL] [Abstract][Full Text] [Related]
5. Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization.
Lee JE; Kim KL; Kim D; Yeo Y; Han H; Kim MG; Kim SH; Kim H; Jeong JH; Suh W
Int J Nanomedicine; 2017; 12():4813-4822. PubMed ID: 28740387
[TBL] [Abstract][Full Text] [Related]
6. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
7. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Fathi Maroufi N; Rashidi MR; Vahedian V; Akbarzadeh M; Fattahi A; Nouri M
Life Sci; 2020 Jan; 241():117106. PubMed ID: 31786193
[TBL] [Abstract][Full Text] [Related]
8. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
9. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
10. Apatinib-loaded nanoparticles inhibit tumor growth and angiogenesis in a model of melanoma.
Zhang J; Liu P; Zhang Z; Han J; Yang X; Wang A; Zhang X
Biochem Biophys Res Commun; 2020 Jan; 521(2):296-302. PubMed ID: 31668370
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage.
Jeong JH; Nguyen HK; Lee JE; Suh W
Int J Nanomedicine; 2016; 11():3101-9. PubMed ID: 27462154
[TBL] [Abstract][Full Text] [Related]
12. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.
Wang Y; Deng M; Chen Q; Li Y; Guo X; Shi P; He L; Xie S; Yu L; Zhang H; Xu B
Eur J Pharmacol; 2019 Jan; 843():145-153. PubMed ID: 30423319
[TBL] [Abstract][Full Text] [Related]
13. Apatinib for the treatment of gastric cancer.
Geng R; Li J
Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
[TBL] [Abstract][Full Text] [Related]
14. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
Scott AJ; Messersmith WA; Jimeno A
Drugs Today (Barc); 2015 Apr; 51(4):223-9. PubMed ID: 26020064
[TBL] [Abstract][Full Text] [Related]
15. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
[TBL] [Abstract][Full Text] [Related]
16. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.
Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Tanaka Y; Yamada S; Naito C; Yamamoto A
Biomaterials; 2018 Feb; 154():74-85. PubMed ID: 29120820
[TBL] [Abstract][Full Text] [Related]
17. Apatinib for molecular targeted therapy in tumor.
Zhang H
Drug Des Devel Ther; 2015; 9():6075-81. PubMed ID: 26622168
[TBL] [Abstract][Full Text] [Related]
18. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Ding J; Chen X; Dai X; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():108-15. PubMed ID: 22503745
[TBL] [Abstract][Full Text] [Related]
20. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
